Conference poster from Pharmaron on translational insights aiding the discovery of selective PARP1 inhibitors with low human dose prediction.

Translational insights support the discovery of selective PARP1 inhibitors with low human dose prediction

This poster showcases the development of a PARP1 inhibitor through a collaboration between Pharmaron and NewBay Pharma. Utilizing integrated multi-disciplinary data, the project identified NB-0290, a potent, orally bioavailable, small molecule selective PARP1 inhibitor for treating BRCA1/2 mutated breast and ovarian cancers. We present translational insights through multi-disciplinary data integration to support the developability assessment of this inhibitor. This work illustrates how cross-discipline integration led to rapidly identifying a high-quality candidate positioned for pre-clinical development.